Welcome to LookChem.com Sign In|Join Free

CAS

  • or

110222-52-1

Post Buying Request

110222-52-1 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • Yohimban-16-carboxylicacid, 11,17-dimethoxy-18-[1-oxo-3-(3,4,5-trimethoxyphenyl)propoxy]-, methylester, (3b,16b,17a,18b,20a)- (9CI)

    Cas No: 110222-52-1

  • No Data

  • No Data

  • No Data

  • Antimex Chemical Limied
  • Contact Supplier

110222-52-1 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 110222-52-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,0,2,2 and 2 respectively; the second part has 2 digits, 5 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 110222-52:
(8*1)+(7*1)+(6*0)+(5*2)+(4*2)+(3*2)+(2*5)+(1*2)=51
51 % 10 = 1
So 110222-52-1 is a valid CAS Registry Number.

110222-52-1Downstream Products

110222-52-1Relevant articles and documents

A structure-function relationship among reserpine and yohimbine analogues in their ability to increase expression of mdr1 and P-glycoprotein in a human colon carcinoma cell line

Bhat,Winter, Mark A.,Pearce,Beck, William T.

, p. 682 - 689 (2007/10/03)

We previously showed that there is a structure-function relationship among reserpine and yohimbine analogues in their ability to inhibit the function of P-glycoprotein (P-gp) and reverse multidrug resistance (MDR). Because some P- gp inhibitors (e.g., verapamil and nifedipine) can increase mdr1 and P-gp expression in human colon carcinoma cell lines, we used our reserpine/yohimbine analogues to determine whether there was a structural requirement for this induction. We found that 10 μM reserpine increased both mdr1 and P-gp expression by 4-10-fold in 48 hr in a human colon carcinoma cell line that expresses moderate levels of mdr1 (LS180-Ad50) but not in several other cell lines that expressed no mdr1. The reserpine/yohimbine analogues rescinnamine, trimethoxybenzoylyohimbine, and LY191401 (compound G), all of which contain the three structural elements used to describe the MDR pharmacophore, also increased both mdr1 and P-gp expression significantly. Despite some exceptions, we found that there was a good association between the ability of these analogues to induce mdr1 and P-gp expression and their ability to reverse vinblastine and doxorubicin resistance, revealing a structure-function relationship for this phenomenon. The increased P-gp expressed by these cells appeared to be functional, as determined by flow cytometric detection of rhodamine 123 retention. The increased expression was suppressed by 5,6-dichloro-1-β-D- ribofuranosylbenzimidazole, an RNA synthesis inhibitor, whereas the protein synthesis inhibitor cycloheximide enhanced the expression several-fold, suggesting that induction of mdr1 by these analogues is regulated at both the transcriptional and post-transcriptional levels. Given that the effect is seen only in cell lines that express some P-gp and is mediated only by active, P-gp-interacting compounds, we speculate that induction of mdr1 and P-gp by these agents may be mediated through a feedback mechanism.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 110222-52-1